[1. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803–820.]Search in Google Scholar
[2. Christians A, Adel-Horowski A, Banan R et al. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathol Commun 2019; 7: 156.]Search in Google Scholar
[3. Saadeh FS, Mahfouz R, Assi HI. EGFR as a clinical marker in glioblastomas and other gliomas. Int J Biol Markers 2018; 33: 22–32.]Search in Google Scholar
[4. Wick W, Weller M, van den Bent M et al. MGMT testing – the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10: 372–385.]Search in Google Scholar
[5. Birkó Z, Nagy B, Klekner Á, Virga J. Novel Molecular Markers in Glioblastoma – Benefits of Liquid Biopsy. IJMS 2020; 21: 7522.]Search in Google Scholar
[6. Taran K, Kobos J, Sitkiewicz A. Estimation of prognostic value of CD44 expression in neuroblastic tumours in children. Folia Neuropathologica 2007; 45: 126–132.]Search in Google Scholar
[7. Schummer P, Kuphal S, Vardimon L, Bosserhoff AK, Kappelmann M. Specific c-Jun target genes in malignant melanoma. Cancer Biology & Therapy 2016; 17: 486–497.]Search in Google Scholar
[8. Tsiambas E, Mastronikolis N, Fotiades PP, Kyrodi E. c-Jun/c-Fos complex in laryngeal squamous cell carcinoma 2020; 25: 618–620.]Search in Google Scholar
[9. Tanyildiz HG, Kaygusuz G, Unal E, Tacyildiz N, Dincaslan H, Yavuz G. The prognostic importance of TGF-β, TGF-β receptor, and fascin in childhood solid tumors. Pediatric Hematology and Oncology 2017; 34: 238–253.]Search in Google Scholar
[10. Dai L, Gast A, Horska A et al. A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-β and receptor genes. Pediatr Blood Cancer 2009; 52: 819–823.]Search in Google Scholar
[11. Zhang L, Liu W, Qin Y, Wu R. Expression of TGF-β1 in Wilms’ tumor was associated with invasiveness and disease progression. J Pediatr Urol 2014; 10: 962–968.]Search in Google Scholar
[12. Bossy-Wetzel E. Induction of apoptosis by the transcription factor c--Jun. The EMBO Journal 1997; 16: 1695–709.]Search in Google Scholar
[13. Raivich G. c-Jun expression, activation and function in neural cell death, inflammation and repair. Journal of Neurochemistry 2008: 107(4): 898–906.]Search in Google Scholar
[14. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. c-Jun phosphorylation in Alzheimer disease. J Neurosci Res 2007; 85: 1668–1673.]Search in Google Scholar
[15. Ramundo V, Giribaldi G, Aldieri E. Transforming Growth Factor-β and Oxidative Stress in Cancer: A Crosstalk in Driving Tumor Transformation. Cancers (Basel) 2021; 13: 3093.]Search in Google Scholar
[16. Huang L, Quan X, Liu Z et al. c-Jun gene-modified Schwann cells: upregulating multiple neurotrophic factors and promoting neurite outgrowth. Tissue Eng Part A 2015; 21: 1409–1421.]Search in Google Scholar
[17. Xiang D-M, Sun W, Zhou T et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut 2019; 68: 1858–1871.]Search in Google Scholar
[18. Blau L, Knirsh R, Ben-Dror I et al. Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation. Proceedings of the National Academy of Sciences 2012; 109: E2875–2884.]Search in Google Scholar
[19. Huang Z, Xia Y, Hu K, et al. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway. J Neurochem 2020; 152: 221–234.]Search in Google Scholar
[20. Taran K, Kobos J, Sporny S. Number of mitotic figures in microscopic picture of nephroblastoma histologic types-estimation of the value of the oldest known prognostic factor. Pol J Pathol 2008; 59: 43–47.]Search in Google Scholar
[21. Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan LC. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol 2017; 34: 320–330.]Search in Google Scholar
[22. Blessing MM, Alexandrescu S. Embryonal Tumors of the Central Nervous System: An Update. Surg Pathol Clin 2020; 13: 235–247.]Search in Google Scholar
[23. Zhao H, Wei J, Sun J. Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy. Int Immunopharmacol 2020; 89: 107101.]Search in Google Scholar
[24. Shao J-B, Gao Z-M, Huang W-Y, Lu Z-B. The mechanism of epithelial--mesenchymal transition induced by TGF-β1 in neuroblastoma cells. International Journal of Oncology 2017; 50: 1623–1633.]Search in Google Scholar
[25. Chen Z, Gao J, Sun J, Wu Z, Wang B. Aminoacylase 1 (ACY-1) Mediates the Proliferation and Migration of Neuroblastoma Cells in Humans Through the ERK/Transforming Growth Factor β (TGF-β) Signaling Pathways. Med Sci Monit 2021; 27: e928813.]Search in Google Scholar
[26. Lolascon A, Giordani L, Borriello A et al. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Br J Cancer 2000; 82: 1171–1176.]Search in Google Scholar
[27. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression. J Mammary Gland Biol Neoplasia 2010; 15: 117–134.]Search in Google Scholar
[28. Zhen Z, Guo X, Liao R, Yang K, Ye L, You Z. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion. Oncotarget 2016; 7: 44340–44349.]Search in Google Scholar
[29. Shi Q, Wu H, Li Y, et al. Inhibition of Wilms’ Tumor Proliferation and Invasion by Blocking TGF-β Receptor I in the TGF-β/Smad Signaling Pathway. BioMed Research International 2020; 2020: 1–10.]Search in Google Scholar
[30. Aref D, Moffatt CJ, Agnihotri S et al. Canonical TGF-β Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development: TGF-β Activity Is Prognostic in Medulloblastoma. Brain Pathology 2013; 23: 178–191.]Search in Google Scholar
[31. Taran K, Frączek T, Sikora-Szubert A et al. The first investigation of Wilms’ tumour atomic structure-nitrogen and carbon isotopic composition as a novel biomarker for the most individual approach in cancer disease. Oncotarget 2016; 7: 76726–76734.]Search in Google Scholar
, 